136 related articles for article (PubMed ID: 20051811)
21. Similar survival with single-agent capecitabine or taxane in first-line therapy for metastatic breast cancer.
Kamal AH; Camacho F; Anderson R; Wei W; Balkrishnan R; Kimmick G
Breast Cancer Res Treat; 2012 Jul; 134(1):371-8. PubMed ID: 22460617
[TBL] [Abstract][Full Text] [Related]
22. Capecitabine and docetaxel combination for the treatment of breast cancer.
Morishita M; Leonard RC
Womens Health (Lond); 2008 Jan; 4():11-22. PubMed ID: 19072447
[TBL] [Abstract][Full Text] [Related]
23. A phase II trial of oral capecitabine in patients with platinum--and taxane--refractory ovarian, fallopian tube, or peritoneal cancer.
Wolf JK; Bodurka DC; Verschraegen C; Sun CC; Branham D; Jenkins AD; Atkinson N; Gershenson DM
Gynecol Oncol; 2006 Sep; 102(3):468-74. PubMed ID: 16516276
[TBL] [Abstract][Full Text] [Related]
24. Survival differences observed in metastatic breast cancer patients treated with capecitabine when compared with vinorelbine after pretreatment with anthracycline and taxane.
Verma S; Wong NS; Trudeau M; Joy A; Mackey J; Dranitsaris G; Clemons M
Am J Clin Oncol; 2007 Jun; 30(3):297-302. PubMed ID: 17551309
[TBL] [Abstract][Full Text] [Related]
25. Capecitabine monotherapy in advanced breast cancer resistant to anthracycline and taxane: A meta-analysis.
Jiang Z; Yang Y; Li L; Yue Z; Lan L; Pan Z
J Cancer Res Ther; 2018 Dec; 14(Supplement):S957-S963. PubMed ID: 30539829
[TBL] [Abstract][Full Text] [Related]
26. [Xeloda (capecetabine) in the treatment of disseminated breast cancer after failure with anthracyclines and taxanes].
Semiglazova TIu; Gershanovich ML
Vopr Onkol; 2001; 47(3):298-302. PubMed ID: 11544827
[TBL] [Abstract][Full Text] [Related]
27. First efficacy results of capecitabine with anthracycline- and taxane-based adjuvant therapy in high-risk early breast cancer: a meta-analysis.
Jiang Y; Yin W; Zhou L; Yan T; Zhou Q; Du Y; Shen Z; Shao Z; Lu J
PLoS One; 2012; 7(3):e32474. PubMed ID: 22396769
[TBL] [Abstract][Full Text] [Related]
28. Oral capecitabine in anthracycline- and taxane-pretreated advanced/metastatic breast cancer.
Wist EA; Sommer HH; Ostenstad B; Risberg T; Bremnes Y; Mjaaland I
Acta Oncol; 2004; 43(2):186-9. PubMed ID: 15163168
[TBL] [Abstract][Full Text] [Related]
29. Treatment patterns in patients with advanced breast cancer who were exposed to an anthracycline, a taxane, and capecitabine: a descriptive report.
Donato BM; Burns L; Willey V; Cohenuram M; Oliveria S; Yood MU
Clin Ther; 2010 Mar; 32(3):546-54. PubMed ID: 20399992
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of S-1 in heavily pretreated patients with metastatic breast cancer: cross-resistance to capecitabine.
Ito Y; Osaki Y; Tokudome N; Sugihara T; Takahashi S; Iwase T; Hatake K
Breast Cancer; 2009; 16(2):126-31. PubMed ID: 18807123
[TBL] [Abstract][Full Text] [Related]
31. Capecitabine plus docetaxel combination therapy.
Verma S; Maraninchi D; O'Shaughnessy J; Jamieson C; Jones S; Martín M; McKendrick J; Miles D; Twelves C; Hornberger J
Cancer; 2005 Jun; 103(12):2455-65. PubMed ID: 15892043
[TBL] [Abstract][Full Text] [Related]
32. Taxane-based regimens as a risk factor for chemotherapy-induced amenorrhea.
Najafi S; Djavid GE; Mehrdad N; Rajaii E; Alavi N; Olfatbakhsh A; Najafi M; Bahrami A; Heidari K
Menopause; 2011 Feb; 18(2):208-12. PubMed ID: 21037487
[TBL] [Abstract][Full Text] [Related]
33. Patient and practice impact of capecitabine compared to taxanes in first-/second-line chemotherapy for metastatic breast cancer.
Schwartzberg LS; Cobb P; Walker MS; Stepanski EJ; Houts AC
Support Care Cancer; 2009 Aug; 17(8):1081-8. PubMed ID: 19148686
[TBL] [Abstract][Full Text] [Related]
34. Capecitabine: a review.
Walko CM; Lindley C
Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
[TBL] [Abstract][Full Text] [Related]
35. Anti-tumor activity of capecitabine and vinorelbine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: findings from the EORTC 10001 randomized phase II trial.
Pajk B; Cufer T; Canney P; Ellis P; Cameron D; Blot E; Vermorken J; Coleman R; Marreaud S; Bogaerts J; Basaran G; Piccart M
Breast; 2008 Apr; 17(2):180-5. PubMed ID: 17976988
[TBL] [Abstract][Full Text] [Related]
36. Capecitabine combined with weekly docetaxel in Chinese patients > 65 years with anthracycline-resistant metastatic breast cancer.
Wang HQ; Qian ZZ; Liu XM; Zhang HL; Li LF; Qiu LH; Hou Y; Zhou SY; Hao XS; Xie CH
Chin Med J (Engl); 2010 Nov; 123(22):3212-6. PubMed ID: 21163117
[TBL] [Abstract][Full Text] [Related]
37. Phase II, double-blind, randomized trial of capecitabine plus enzastaurin versus capecitabine plus placebo in patients with metastatic or recurrent breast cancer after prior anthracycline and taxane therapy.
Clemons M; Joy AA; Abdulnabi R; Kotliar M; Lynch J; Jordaan JP; Iscoe N; Gelmon K
Breast Cancer Res Treat; 2010 Nov; 124(1):177-86. PubMed ID: 20814815
[TBL] [Abstract][Full Text] [Related]
38. Single-agent capecitabine: a reference treatment for taxane-pretreated metastatic breast cancer?
Seidman AD; O'Shaughnessy J; Misset JL
Oncologist; 2002; 7 Suppl 6():20-8. PubMed ID: 12454316
[TBL] [Abstract][Full Text] [Related]
39. The role of capecitabine in first-line treatment for patients with metastatic breast cancer.
Gelmon K; Chan A; Harbeck N
Oncologist; 2006; 11 Suppl 1():42-51. PubMed ID: 16971739
[TBL] [Abstract][Full Text] [Related]
40. Economic evaluation of capecitabine as adjuvant or metastatic therapy in colorectal cancer.
Best JH; Garrison LP
Expert Rev Pharmacoecon Outcomes Res; 2010 Apr; 10(2):103-14. PubMed ID: 20384557
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
